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Aim: Indirect treatment comparisons are used when no direct comparison is available. Comparison net-
works should satisfy the transitivity assumption, that is, equal likelihood of treatment assignment for
a given patient based on comparability of studies. Materials & methods: Seven criteria were evaluated
across 18 randomized controlled trials in psoriatic arthritis: inclusion/exclusion criteria, clinical trial de-
sign and follow-up, patient-level baseline characteristics, disease severity, prior therapies, concomitant
and extended-trial treatment and placebo response differences. Results: Across studies, placebo was a
common comparator, and key efficacy end points were reported. Collectively, several potential sources
of insufficient transitivity were identified, most often related to trial design and population differences.
Conclusion: Potential challenges in satisfying transitivity occur frequently and should be evaluated thor-
oughly.
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Randomized controlled trials (RCTs) often compare new drugs with placebo [1,2]. In the absence of head-to-head
studies comparing two active agents, indirect treatment comparisons (ITCs) with a common drug comparator can
be used to estimate each drug’s relative clinical effectiveness. For example, using a common treatment arm B, results
from a clinical trial directly comparing drugs B and A can be indirectly compared with another, separate clinical
trial directly comparing drugs B and C [2–4]. As shown in Supplementary Figure 1, with network meta-analyses
(NMAs), multiple ITCs can be joined, either with or without direct comparisons (trials), as long as there is a
common treatment comparator.
ITC is a valid and robust statistical approach when the transitivity assumption is met [1,4,5]. Within a treatment
network containing either direct or both direct and indirect comparisons, the transitivity assumption states equal
likelihood of receiving any of the treatments for each patient [3]. Assuming transitivity requires satisfaction of a
complex standard that joins several points of consideration to compare study similarities (comparability) across the
treatment network [1,4,5]. Although various discussions in the literature offer general advice on assessing studies
for both conceptual and epidemiological differences, the authors did not find a single, centralized source in the
literature to guide the evaluation of transitivity. For example, the findings from an NMA can be more precise when
there is sufficient between-study similarity in clinical trial designs and balance of patient baseline characteristics
that have potential treatment-modifying effects (i.e., effect modifiers). If these different study parameters and
patient characteristics are effect modifiers, then combined study results can be biased, either overestimating or
underestimating the significance of the relative treatment effect [2,6–8]. In these cases, guidelines from the literature
suggest that ITC should not be performed, and transitivity can be considered unsatisfied [1,3,9]. Furthermore, if
baseline study characteristics that are not effect modifiers are distributed too unevenly across studies (which can
be evaluated with χ2 tests or t-tests, for example), then it can be challenging to infer comparative treatment effect
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estimates to broader patient populations [10,11]. These interpretive challenges do not necessarily invalidate the ITC;
however, understanding the potential influence of the baseline differences across studies is clinically relevant [11].
When treating potentially different patient populations, this can be a strong theme during evaluation of transitivity.
Consistency, which represents the degree of difference between direct and indirect comparisons, can be used
to help assess transitivity [12]. To satisfy consistency within the same network, estimates from direct comparison
paths would approximate estimates from an indirect path. However, consistency can only be evaluated when there
are both indirect and direct paths for the same pair of drugs being compared [3,12]. Furthermore, consistency
alone only considers end results, not study and patient characteristics; thus, measuring consistency is not enough
evidence to confirm transitivity. While statistical tests can help to gather information that demonstrate potential
transitivity violations and challenges (e.g., significant imbalances in effect modifiers and clinical variables associated
with prognosis), performing a comprehensive transitivity evaluation involves collecting multiple types of evidence.
Thus, even if an ITC is technically feasible, the validity of ITCs should be rigorously evaluated during the review
of the studies and before performing calculations.
In the last 15 years, the number of systematic reviews and NMAs has grown exponentially, including ITCs
within clinical rheumatology [1,13,14]. With limited practical guidance to assess transitivity, networks are becoming
increasingly large and complex, potentially including increased sources of heterogeneity across trials, which can be
problematic. In the case of psoriatic arthritis (PsA), for example, there is a clear opportunity to develop networks
of trials evaluating many treatments, including disease-modifying antirheumatic drugs (DMARDs) and biologic
therapies consisting of TNF-α blockers and IL-12/23, IL-17 and IL-23 inhibitors (Supplementary Figure 1). It is
less clear whether such comparisons would sufficiently address the transitivity requirement. We developed criteria
to assess transitivity and applied these criteria to PsA trials, using the new treatment apremilast as an example case
for an NMA, to better define the opportunities and challenges in conducting NMAs appropriately. By evaluating
PsA studies for transitivity, we aimed to further refine existing discussion surrounding transitivity into practical and
specific guidance to inform transitivity requirements for NMAs.
Many treatment options and variabilities exist in PsA drug sequencing based on patient characteristics and
preference, disease manifestation and drug response. Pathways traditionally begin with systemic therapy (e.g., non-
steroidal anti-inflammatory drugs or DMARDs, such as methotrexate [MTX]), then vary according to response
and tolerability. Biologic therapies for PsA, including but not limited to etanercept, infliximab, adalimumab or goli-
mumab, target TNF and are administered by injections or infusions. The IL-12/23 and IL-17 biologic inhibitors
act on different parts of the inflammatory cascade. Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor
that regulates the inflammatory cascade [15]. In four randomized, placebo-controlled studies, apremilast treatment
improved clinical disease outcomes in patients with active PsA [15,16]. To date, apremilast has not been compared
directly with other monotherapies in head-to-head studies, including conventional DMARDs or biologics. At the
time this analysis was performed, peer-reviewed published NMAs for PsA treatments did not include apremilast or
they did not evaluate transitivity thoroughly [6,17–20]. Because head-to-head comparative evidence is lacking, a valid
ITC of apremilast and its active comparators was chosen as a case study to evaluate another potential treatment
option for PsA [21].
Materials & methods
Overview
To assess potential challenges in satisfying transitivity within a network of apremilast and other PsA therapies,
several literature searches were performed, as summarized in Figure 1. Three distinct, targeted literature searches
were conducted to source transitivity discussion, definitions, examples and stated criteria in peer-reviewed literature;
any discussion of transitivity (including effect modification) in PsA studies and the broader rheumatology literature;
and any assessment of transitivity in current NMAs comparing PsA clinical trials. From these targeted searches,
any existing methods for evaluating transitivity, including clinical and patient factors contributing to insufficient
transitivity, were organized into five general guidelines of transitivity. Next, a systematic literature search, following
the Cochrane guidelines for systematic review, was performed to identify PsA studies to be included in the proposed
NMA. Clinical and patient factors extracted from the selected studies were applied to the sourced transitivity
descriptions to create more specific, centralized transitivity criteria. From these formalized transitivity criteria, the
appropriateness of including the selected PsA studies in the NMA was reported.
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Literature searches Search result synthesis
Clarifying transitivity-related
terms/definitions
Gathering multi-sourced
transitivity guidance
Identifying clinical and patient
characteristics
Created centralized transitivity
criteria
Case study:
transitivity in PsA
Randomized controlled trials
Systematic literature review –
apremilast + relevant
comparators
1) Transitivity guidelines or
discussion in ITC manuscripts
2) Transitivity and/or EM in
PsA/rheumatology
3) Transitivity in NMA of
PsA clinical trials
Targeted literature reviews:
Figure 1. Overview of literature searches and evidence generation applied to newly centralized transitivity criteria.
EM: Effect modification; ITC: Indirect treatment comparison; NMA: Network meta-analysis; PsA: Psoriatic arthritis.
Search strategy & data extraction
The systematic literature search identified relevant studies in the databases Medline via PubMed, EMBASE, the
Cochrane Central Register of Controlled Trials and clinicaltrials.gov. Eligible studies were RCTs of current PsA
treatments published up to 1 March 2015. Treatments included in the search were MTX; the biologics adalimumab,
certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab; and the PDE4 inhibitor
apremilast.
The Cochrane guidelines were followed during the selection of full-text articles [22]. At least two reviewers selected
the articles from a title and abstract review, and a third reviewer was enlisted for any disagreements. English-language
studies needed to report at least one of the key efficacy or safety end points and include separate reporting of patients
who were at least 18 years of age. Exclusion criteria eliminated nonrandomized clinical studies, single-arm studies,
studies without a control arm (placebo) and studies without full-text publications. A PRISMA flow diagram for
study selection was created (Supplementary Figure 2).
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To evaluate the RCTs against the newly centralized transitivity criteria, the following study characteristics were ex-
tracted: inclusion criteria, exclusion criteria, drug comparator, participant age, sex, duration of PsA disease in years,
mean tender joint count at study baseline, prior use of DMARDs or biologics, time of efficacy assessment/crossover
design, concomitant DMARD or MTX use and placebo response rates based on the American College of Rheuma-
tology response criteria (ACR20 and ACR50). Also, it was recorded if the study authors evaluated each of these
variables for potential treatment effect modification or prognostic significance and what their methods were for
addressing effect modification and prognostic factors.
Transitivity in the literature
From the targeted literature searches, it was found that the term transitivity was associated with similarity assumption
or used interchangeably with comparability [4,23–27]. The similarity assumption was used to describe both finding
a true (i.e., similar) treatment effect between two interventions across multiple studies as well as used to describe
a network having similar characteristics between studies. However, for the similarity assumption and discussions
of comparability, no formal definition or criteria to assess appropriateness of an ITC were found. Furthermore,
applying concepts of similarity or comparability alone can lead to a narrower understanding that all study and
patient characteristics must be mostly uniform to assume transitivity. In fact, valid ITCs can be performed as long
as there is similar distribution of the mutual effect modifiers between studies [1,5,12,27]. From this literature, effect
modification is defined as the presence of one or more variables that changes the effect estimate for treatment on
a given scale of measure [28]. Specifically, the alteration in treatment effect is different within different subgroups
of the same patient characteristic, which may be statistically demonstrated through a test for interaction. Statistical
interaction is considered if the combined effect of two factors, such as PsA treatment and PsA disease subtype, is
greater than would be expected by the sum or multiplication of their independent effects [29]. Across studies, similar
distribution of effect modifiers can be constructed through population-adjustment methods, including propensity
score weighting and simulated treatment comparison, if at least one individual, patient-level dataset is available
for adjustment [28]. However, addressing effect modification is only one of the five different guiding principles
found from different sources during the targeted literature searches that describe transitivity [1,5,30]. Ideas related
to transitivity were found from different literary sources and organized below into the five general guidelines.
Current transitivity discussions found in the literature
Search results are organized into five guiding themes: between studies, there exists an anchor treatment, such as
a placebo, that is similar in all studies being compared; the selection of studies for the network should not be
solely motivated by an expected outcome, or results can be subject to bias; there are true comparative treatment
effects between two interventions that can be measured across multiple studies, so that a network of multiple
studies is justified; similar distribution of effect modifiers is necessary between studies, such as proportion of older
versus younger patients, or poorer versus fitter baseline performance status; and any of the treatments could be
appropriately compared in a randomized study based on similar disease indication.
Results
Evidence network
After title and abstract review, 82 publications were selected for full-text review. Some studies were associated with
more than one publication, which resulted in the identification of 25 unique clinical trials (Supplementary Figure
2). Applying the inclusion and exclusion criteria and designating placebo as the comparator for a potential NMA, we
were able to link 18 unique RCTs (Table 1) [15,16,31–46] for apremilast and seven active comparators (adalimumab,
certolizumab pegol, etanercept, golimumab, infliximab, secukinumab or ustekinumab). Of note, two studies
of MTX monotherapy were excluded because they lacked the required clinical response variables [47,48], and one
apremilast abstract from 2014 (PALACE 4) was excluded for a similar lack of needed extraction variables [49]. During
analysis, additional results from McInnes et al. for secukinumab and two follow-up studies for apremilast [15,16,31]
were discovered and added. A graphic of the final network is provided in Supplementary Figure 1.
Development of the centralized transitivity criteria
Extraction of the patient and clinical trial characteristics of the selected PsA RCTs helped to identify specific
variables that should be evaluated for transitivity across studies. This identification supported the development of
the following transitivity criteria, with the aim of providing newly formalized, specific guidance. These centralized
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Table 1. Selected clinical studies.
Name Study (year) Treatment Comparator Ref.
PALACE 1 Kavanaugh (2014) Apremilast 20 mg OR 30 mg B.I.D. Placebo [33]
PALACE 2 Cutolo (2016) Apremilast 20 mg OR 30 mg B.I.D. Placebo [15]
PALACE 3 Edwards (2016) Apremilast 20 mg OR 30 mg B.I.D. Placebo [16]
PSA-001 Schett (2012) Apremilast 20 mg B.I.D. OR 40 mg QD Placebo [34]
ADEPT Mease (2005) Adalimumab 40 mg Q2W Placebo [39]
M02-570 Genovese (2007) Adalimumab 40 mg Q2W Placebo [37]
RAPID-PsA Mease (2014) Certolizumab pegol 200 mg Q2W OR Certolizumab pegol 400 mg Q4W Placebo [36]
Mease (2000) Mease (2000) Etanercept 25 mg twice weekly Placebo [40]
Mease (2004) Mease (2004) Etanercept 25 mg twice weekly Placebo [41]
GO-REVEAL Kavanaugh (2009) Golimumab 50 mg OR 100 mg Q4W Placebo [38]
IMPACT Antoni (2005) Infliximab 5 mg/kg weeks 0, 2, 6 and 14 Placebo [45]
IMPACT 2 Antoni (2005) Infliximab 5 mg/kg weeks 0, 2, 6 and 14 Placebo [42]
PSUMMIT 1 McInnes (2013) Ustekinumab 45 mg OR 90 mg at weeks 0 and 4, and every 12 weeks thereafter Placebo [35]
PSUMMIT 2 Ritchlin (2014) Ustekinumab 45 mg OR 90 mg at weeks 0 and 4, and every 12 weeks thereafter Placebo [32]
Gottlieb (2009) Gottlieb (2009) Ustekinumab 90 mg OR 63 mg QW Placebo [43]
Atteno (2010) Atteno (2010) Etanercept 25 mg twice weekly OR infliximab 5 mg/kg every 6–8 weeks Adalimumab 40 mg
Q2W
[46]
McInnes (2014) McInnes (2014) Secukinumab 10 mg/kg Q3W (two doses) Placebo [44]
FUTURE 2 McInnes (2015) Secukinumab 75 mg OR 150 mg OR 300 mg QW to week 4, then Q4W Placebo [31]
B.I.D.: Twice per day; QD: Daily; QW: Weekly; Q2W: Every 2 weeks; Q3W: Every 3 weeks; Q4W: Every 4 weeks.
transitivity criteria were enlisted to determine if an ITC of the linked PsA RCTs could be appropriately performed.
The seven transitivity criteria follow:
• Inclusion/exclusion criteria: study participants should have similar trial eligibility, such as the same disease and
indications for treatment, where they could be randomized to any of the trials in the network [1,4,50]. At the same
time, exclusion criteria for comorbidities such as concurrent malignancies and infections should be comparable
between studies [31,51,52].
• Clinical trial design and follow-up: clinical trial designs should be comparable [4], with similar treatment
durations [3], methods for identifying and measuring treatment outcomes [9] and length of follow-up periods [9].
For example, treatment crossover (switching) prior to the initial efficacy assessment introduces bias in measuring
true effect depending how data are handled postswitching [53].
• Baseline characteristics: patient factors such as age [3,54] and duration of disease [21] can modify relative treatment
effects within PsA and thus should have similar distributions between all study arms to minimize biases in
estimating effect size [1,4,9]. During randomization, patients may be stratified by potential prognostic factors that
are directly associated with outcomes such as survival and disease response.
• Disease severity or subgroups: within disease characteristics, severity and subtype (‘disease indication’) [1,3,4]
can also modify relative treatment effects (e.g., differences in baseline swollen joint counts between treatment
groups) [21].
• Prior therapies: patients with past exposure to related PsA therapies may demonstrate relatively lower treatment
efficacy to the new drug and thus should be evenly distributed between study arms [6,21,55].
• Concomitant and extended-trial treatment: study participants for a new drug may continue or add on systemic
treatments such as MTX, and varying doses over time and between study groups can be an important source of
heterogeneity [3,9,21,32,56].
• Placebo response: placebo groups may have higher than expected clinical responses, which can be associated
with measuring lower relative treatment effects [57] and can convey the presence of confounding by unadjusted
baseline risks or clinical trial differences [1,5,58]. These sources of bias can be inconsistent across different study
protocols.
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Data extraction & transitivity evaluation
Among the selected studies, sufficient pre-identified study variables were available to perform cross-study compar-
isons (Table 2) [15,16,31–46]. The apremilast trials (PALACE 1 [33], PALACE 2 [15] and PALACE 3 [16]) were considered
the reference studies used to evaluate transitivity in comparison with the remaining studies in the network. Patients
from these studies were permitted past exposure to biologics and DMARDS and could have concomitant use of
MTX, sulfasalazine, leflunomide, low dose oral corticosteroid or nonsteroidal anti-inflammatory drugs during the
studies. Further study data that supported the identification of transitivity violations are summarized in Table 2.
Data extraction revealed potential sources of between-study clinical and methodological heterogeneity, and most
study authors did not report statistical evaluation of treatment effect modification within their studies. Across the
network, transitivity violations related to all seven tenets were found, and major themes included clinical trial design
(crossover, timing of efficacy assessment and follow-up) and population differences (baseline disease characteristics,
prior and concomitant medications and placebo response rates). Table 3 summarizes the most evident transitivity
violations (or none) for each included study [15,16,31–46].
Study differences in data reported that contributed to transitivity violations were especially notable when
comparing apremilast with the biologic studies. For instance, the apremilast studies included treatment crossover
(early escape), enabling nonresponders in the placebo groups to be re-randomized [15,16,33,34]. However, efficacy end
points occurred prior to re-randomization, which limited a potential source of measurement bias. Of the biologic
studies, six did not report a crossover design (Transitivity Criteria #2); however, two studies permitted early escape
to investigational treatment after initial treatment response measurements. Of the eight biologic studies that did
have patient crossover, different methods were used to account for missing variables, making them difficult to
compare. Of note, it is possible that crossover or re-randomization was performed but not explicitly reported in the
article. As shown in Table 2, duration of PsA disease at baseline ranged from 3 years to nearly 12 years (Transitivity
Criteria #3), while the literature demonstrates that outcomes are less favorable with a longer PsA symptom duration
or time to diagnosis [59–61]. Across studies, mean tender joint counts at baseline ranged from 12 to 29 (Transitivity
Criteria #4). Almost all participants in three of the four apremilast studies (PALACE 1, 2 and 3 [15,16,33] but not
PSA-001 [34]) had prior conventional DMARD use, while 43–71% in all four apremilast studies had concomitant
DMARD use [15,16,33,34]. Six of the nonapremilast studies also distinguished between proportions of patients with
prior (59–100%) and concomitant (20–90%) use, while it was unclear if the remaining studies distinguished
between prior and concomitant use (Transitivity Criteria #5). Concomitant treatments were similarly heterogenous
(e.g., MTX use 20–90%) across all studies (Transitivity Criteria #6), as was placebo response (9–44%), measured
as ACR20 (Transitivity Criteria #7). Furthermore, many studies did not report prior or concomitant medication
use. In addition, there was variability in the years the studies were published and the countries from which patients
were recruited. While a specific measured variable representing access issues was not available, year of publication
or country of study can convey different accessibilities based on the treatment’s availability in a healthcare system at
that time. These factors may have resulted in differences such as, but not limited to, disease severity, prior therapies
received and concomitant medications, making it difficult to compare results across studies. In summary, different
inclusion and exclusion criteria may have been used across studies.
Effect modification
Within most of the extracted RCTs, authors enlisted various methods to minimize baseline imbalances in patient,
disease and treatment characteristics (Table 4) [15,16,31–46]. Although none of the study authors used the terms
‘prognostic factor’ or ‘effect modifier’ when reporting stratification, 15 of the 18 RCTs specified stratification during
randomization. Participants were stratified according to baseline use of DMARDs [15,16,32–35,37–42], prior exposure
to biologics [31,36,43] or no stratification factor was reported [44–46]. Of the studies not reporting stratification,
all but one reported performing subgroup analyses to determine any difference in treatment efficacy by patient
characteristic [44,46].
During analyses, nine studies [15,16,33–35,37–40], as identified in Table 4, specified testing separate treatment effects
by baseline MTX or DMARD use with Mantel–Haenszel stratification or analysis of variance regression, including
the apremilast studies. However, posttrial, only two studies specifically addressed (and refuted) the significance of
a statistical interaction term [34,44]. Of the remaining 16 studies that were included, there were varying levels of
reporting rigor for subgroup analyses addressing more general treatment-modifying effects [15,16,31–33,35–43,45,46]. For
at least one baseline variable, four studies provided statistical refutation of effect modification [16,37–39], one study [34]
reported similar numeric proportions of responders between subgroups, five studies provided similar evaluation
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Table 3. Potential or unknown violations to transitivity assumptions.
Name Study (year) Summary Ref.
PALACE 1 Kavanaugh 2014 No deviation (reference for comparison) [33]
PALACE 2 Cutolo (2016) No deviation (reference for comparison) [15]
PALACE 3 Edwards (2016) No deviation (reference for comparison) [16]
PSA-001 Schett (2012) Structural: 12-week study vs 16-week PALACE studies [34]
ADEPT Mease (2005) Structural: no crossover design; population – prior medications [39]
M02-570 Genovese (2007) Structural: no crossover design; population – prior medications [37]
RAPID-PsA Mease (2014) No significant deviations [36]
Mease (2000) Mease (2000) Structural: no crossover design [40]
Mease (2004) Mease (2004) Structural: no crossover design; population – missing variables on prior medications [41]
GO-REVEAL Kavanaugh (2009) Population: prior biologic use excluded [38]
IMPACT Antoni (2005) Population: PsA duration [45]
IMPACT 2 Antoni (2005) Population: prior biologic use excluded [42]
PSUMMIT 1 McInnes (2013) Missing variables on prior and concomitant medications [35]
PSUMMIT 2 Ritchlin (2014) Population: PsA duration shorter, prior biologic use with lower clinical responses [32]
Gottlieb (2009) Gottlieb (2009) Lower concomitant DMARDs use [43]
Atteno (2010) Atteno (2010) Structural: no crossover design; population – lower TJC, exclusions for biologics; study
design: missing data on concomitant medications
[46]
McInnes (2014) McInnes (2014) Structural: no crossover design, other concomitant medications [44]
FUTURE 2 McInnes (2015) Missing variables on PsA duration, prior and other concomitant medications [31]
DMARD: Disease-modifying antirheumatic drug; PsA: Psoriatic arthritis; TJC: Tender joint count.
plus graphical evidence [32–36] and five studies [15,40,41,43,45] stated in the text that differences in treatment effects
by subgroups were not evident. One study [46] did not report analyses for potential baseline imbalances. Some
study authors, as noted in Table 4, cited smaller patient populations as challenging their ability to statistically test
subgroups [34,42,44].
While most studies reported stratification for one patient characteristic, effect modification was not refuted for
remaining variables. As previously noted, effect modification is detected on a specific scale (e.g., additive treatment
effect); however, none of the studies specified the models used to estimate efficacy. Some studies [31,33,36,44],
as described in Table 4, conveyed potentially higher treatment efficacy in patients unexposed to certain prior
therapies. For example, Kavanaugh et al. [33] stratified participants by baseline use of DMARDs and graphically
depicted potential effect modification for past exposure to biologic agents. The authors noted relatively lower
clinical responses in biologic-experienced patients when compared with biologic-naive patients receiving apremilast
or placebo [33]. Similarly, Mease et al. [36] stratified participants by prior TNF inhibitor exposure and reported
somewhat dissimilar proportions of clinical response by concomitant DMARDs, which potentially demonstrated
effect modification (Supplementary Material). Most study authors did not statistically evaluate treatment-effect
modification within their studies, making it difficult to determine within-study, treatment-modifying biases. On
the other hand, if an effect modifier was identified at the trial level, the distribution of this variable could be assessed
across the network.
Separate from the systematic literature review, our targeted literature search for developing transitivity criteria
found studies and published guidelines addressing effect modification within PsA and rheumatoid arthritis (RA)
disease studies. Actual detection of effect modification was demonstrated in three RA studies, and effect modifiers
included age, swollen joint count, prior DMARD use, concomitant DMARD use, concomitant MTX use and
baseline risk (placebo effect) [21,26,29]. Additionally, Christensen et al. [21] potentially detected a modification of
the treatment effect based on the disease duration but were unable to demonstrate its independent relative effects
from prior DMARD use. Additional PsA, RA and NMA quality guidelines discuss and encourage testing for
potential sources of effect modification [5] such as patient comorbidities [51,52] and gender (Consensus Working
Party 2013); however, none of the extracted RCTs tested against these potential biases. Furthermore, two full
publication NMAs that included apremilast cited variations in study populations and a lack of covariate adjustment
in the meta-regressions as limitations; however, potential biases related to transitivity were not measured [18,20].
Within our network, the PALACE 4 abstract was excluded for lack of the reporting variables traditionally available
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Table 4. Consideration and controls for baseline differences.
Name Study (year) Stratification Evidence reporting Additional investigator observations Ref.
PALACE 1 Kavanaugh (2014) Baseline DMARD use Graphical and numeric reporting of
higher treatment response in biologic
naive
Textual refutation of DMARD use
Regardless of biologic history, treatment
statistically superior over placebo
Patient characteristics were consistent
across biologic history
[33]
PALACE 2 Cutolo (2016) Baseline DMARD use Textual refutation of prior biologic and
baseline DMARD use
Lower treatment efficacy is noted in
nonconcomitant DMARD use but not
statistically tested
[15]
PALACE 3 Edwards (2016) Baseline DMARD use Statistical testing and refutation
(supplement) of prior biologic and
baseline DMARD use
Similar treatment efficacy regardless of
other medications
Highest but not statistically superior
response in biologic naive
[16]
PSA-001 Schett (2012) Baseline MTX use Numeric refutation of baseline MTX use
Numeric conveyance of different
treatment efficacy by PsA subtype
Small patient subgroups challenged
statistical testing
[34]
ADEPT Mease (2005) Baseline MTX use Statistical testing and refutation of
baseline MTX use and extent of
psoriasis BSA
Proportion of improvement similar
regardless of MTX use through week 24
Concludes that interaction of treatment
and MTX to be determined
Exclusion criteria for any other DMARD
[39]
M02-570 Genovese (2007) Baseline DMARD use Statistical testing and refutation of
baseline DMARD use
Response in the treatment arm was
reached for 15 of 29 men (52%) and 5
of 22 women (23%)
[37]
RAPID-PsA Mease (2014) Prior TNFi exposure
and investigational
site
Graphical and numeric refutation of
prior TNFi exposure
Numeric refutation of concomitant
DMARD use
Somewhat dissimilar proportions of
response by prior DMARD (supplement)
[36]
Mease (2000) Mease (2000) Baseline MTX use Textual refutation of treatment
interaction by baseline MTX use
Subgroup analyses showed no
differences in treatment efficacy by
MTX or corticosteroid use, nor by
baseline PASI score (data not shown)
[40]
Mease (2004) Mease (2004) Baseline MTX use Textual refutation of sex and baseline
MTX use
No significant differences in response
were observed from sensitivity analyses
of subgroups
[41]
GO-REVEAL Kavanaugh (2009) Baseline MTX use Statistical testing and refutation of
baseline MTX use
− [38]
IMPACT Antoni (2005) Not reported Statistical testing and refutation of
baseline DMARD or specific MTX use
− [45]
IMPACT 2 Antoni (2005) Baseline MTX use and
investigational site
Textual refutation of baseline DMARD
or specific MTX use
Small patient group sizes may have
made higher level responses to appear
more frequently in non-MTX users
[42]
PSUMMIT 1 McInnes (2013) Baseline MTX use Graphical and numeric refutation of
baseline MTX use
Crossover at week 16, numeric
reporting of efficacy starts at week 24
[35]
PSUMMIT 2 Ritchlin (2014) Baseline MTX use Graphical and numeric conveyance of
higher placebo response in MTX users
and anti-TNF naive statistical refutation
of anti-TNF exposure
Crossover at week 16, numeric
reporting of efficacy starts at week 24
[32]
Gottlieb (2009) Gottlieb (2009) Prior anti-TNF
exposure and
investigational site
Textual reporting of adjustment during
analyses for anti-TNF exposure
Patients with anti-TNF exposure were
limited to about 20% of the study
population
[43]
Atteno (2010) Atteno (2010) Not reported Not reported While stratification was not reported,
exclusion for prior anti-TNFi exposure
[46]
McInnes (2014) McInnes (2014) Not reported Graphical and numeric reporting of
differences in treatment efficacy by
TNFi exposure
Small patient subgroups challenged
statistical testing
Treatment effect appears greater in
TNFi naive
[44]
FUTURE 2 McInnes (2015) Prior TNFi use Statistical refutation of prior TNFi
exposure and treatment interaction
Textual refutation of MTX use
Magnitude of response higher in TNFi
naive, but both exposure groups
demonstrated significant treatment
effects
[31]
DMARD: Disease-modifying antirheumatic drug; MTX: Methotrexate; PASI: Psoriasis area and severity index; PsA: Psoriatic arthritis; TNFi: Tumor necrosis factor inhibitor.
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for full publications, while both full publication NMAs included the PALACE 4 abstract in their analysis. Another
NMA, available as an abstract, aimed to test treatment efficacy of several treatments, including apremilast, according
to biologic-exposed and biologic-naive subgroups [19]. However, due to limited data, trends within the biologic-
exposed subgroup could not be developed. Another abstract reporting similar NMA methodology also performed
separate analyses by biologic status, although no other patient characteristics were identified [62].
Discussion
The systematic literature review for PsA RCTs for systemic treatments or monotherapies resulted in a potential
network of 18 unique RCTs with placebo comparators. Key patient, disease, treatment and response variables
were extracted and evaluated for potential biases related to uneven distribution of potential effect modifiers and
other transitivity violations. Comprehensive transitivity criteria were developed from evaluating study differences
between the 18 RCTs and a targeted literature review of existing guidelines and relevant disease publications.
Based on existing NMA quality guidelines, past transitivity descriptions and our own transitivity criteria, there
would be numerous challenges concerning comparability before conducting an ITC among the extracted PsA
RCTs. While most study methods included stratification on a select baseline covariate, other potential sources of
transitivity violations, including the clinical trial structure and design (crossover, length of study), were still evident.
Post-trial, most authors discussed at least one method of subgroup analyses to evaluate study imbalances; however,
only five studies included statistical evidence. Although sensitivity analyses and/or adjusting for confounding while
performing an NMA may help to balance study and patient characteristics, if excluding studies, the quantity
of information lost to achieve sufficient transitivity could limit the interpretative results. This case study of
PsA highlights the growing trend of publishing NMAs within clinical rheumatology, while guidance to address
transitivity is still under development and not routinely applied [12,13].
With the lack of specific guidance to assess transitivity, existing NMAs for PsA and RA often assume transitivity
to perform comparisons [1,4,5,9]. While guidelines in the literature addressing quality issues in NMA are increasing,
such as the Grading of Recommendations Assessment, Development and Evaluation (GRADE) [30] and criteria by
the Comparing Multiple Interventions Methods Group (Cochrane), our transitivity criteria provide specific and
necessary detail to systematically check key study variables for between-study comparability when considering ITC.
Limitations
Transitivity considerations are limited by the ability to identify sources of heterogeneity based on individual trial
reporting. Often there is potential for unobserved sources of bias or unreported study variables that limit valid
comparisons between studies [1]. Particularly in the case of effect modifiers, unknown imbalances can introduce biases
to both within- and between-study effect estimates. For example, in the extracted PsA RCTs, year of publication
or country of study can convey different accessibilities based on the treatment’s availability in a healthcare system
at that time. However, a specific measured variable representing access issues was not available. Additionally,
comorbidity distributions were not part of the study extraction list because they are often unreported in PsA studies
or only severe comorbidities are reported as exclusion criteria. Nevertheless, clinical or more conceptual rather than
quantitative judgment can support decision-making when there is no covariate measure available (e.g., regarding
differences in study eligibility or disease indication). The greater awareness and transparent reporting of these
study characteristics and methodologies will help support robust ITC to inform clinicians, patients and healthcare
decision-makers when deciding courses of treatment among the large array of therapies for a given indication.
Conclusion
Using PsA RCTs as a case study, 18 eligible studies were available to conduct the NMA. Among the extracted
studies were numerous violations of transitivity for the proposed network. Varying efforts, including reporting, were
performed to identify potential effect modifiers that could introduce bias into the network. However, between-study
heterogeneity is often underevaluated in published ITCs. More formal and comprehensive transitivity criteria were
developed with the aim of informing the appropriateness and validity of future ITCs for clinical trials. Unbiased
and informed decision-making is crucial for high-quality patient care.
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Summary points
• An indirect treatment comparison (ITC) is used to compare two or more treatments when no direct, head-to-head
study comparisons are available.
• To provide appropriate comparisons, the treatment network should satisfy the transitivity assumption, that is,
equal likelihood of treatment assignment for a given patient based on comparability of studies.
• This case study of psoriatic arthritis (PsA) aimed to develop a criterion-based approach to evaluate challenges in
satisfying the transitivity assumption and select appropriate studies for ITC. PsA was used as a case study to
demonstrate study selection and network evaluation after performing a systematic literature review for ITC
analysis.
• We developed a framework to determine the plausibility of study comparisons and applied it to 18 RCTs,
comparing apremilast with seven other treatments in PsA with no available direct comparisons.
• Seven criteria were evaluated to include studies in the ITC: inclusion/exclusion criteria; clinical trial design and
follow-up; baseline characteristics; disease severity subgroups; prior therapies; concomitant and extended-trial
treatment and differences in placebo response.
• To enable the generation of robust and reliable ITC estimates, several key patient and trial characteristics from
the selected studies and examples of imbalanced baseline characteristics and other clinical trial design differences
potentially introducing biases due to confounding were identified.
• However, most studies were proven to contribute to a lack of transitivity in the network due to disparities in
clinical trial design (including crossover, time of efficacy assessment and follow-up) and population differences
(baseline disease characteristics, prior and concomitant medications and placebo response rates).
• The inability to satisfy the transitivity assumption often results from multiple challenges. Transitivity assumptions
must be evaluated thoroughly, as biases due to confounding are often underevaluated when performing ITC.
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